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Useful Predictor of Cardiovascular Disease Risk
Than C-Reactive Protein in Older Men With and
Without Pre-Existing Cardiovascular Disease
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Objectives We aimed to compare the predictive capabilities of N-terminal pro-brain natriuretic peptide (NT-proBNP) and
C-reactive protein (CRP) for risk of cardiovascular disease (CVD) in older men with and without pre-existing CVD.
Background The clinical utility of NT-proBNP in CVD risk stratification in the general population remains unclear.
Methods A prospective study of 3,649 men age 60 to 79 years were followed for a mean of 9 years during which there
were 608 major CVD events (major fatal and nonfatal coronary heart disease, stroke, and CVD death).
Results NT-proBNP was significantly associated with risk of all major CVD outcomes after adjustment for CV risk factors
in both men with and without CVD. The adjusted standardized hazard ratios for CVD events in those without pre-
existing CVD and those with pre-existing CVD were 1.49 (95% confidence interval [CI]: 1.33 to 1.65) and 1.52
(95% CI: 1.33 to 1.75), respectively. CRP was associated with CVD outcomes only in men without pre-existing
CVD (adjusted standardized hazard ratios: 1.22 [95% CI: 1.10 to 1.34] and 1.00 [95% CI: 0.86 to 1.38], respec-
tively). NT-proBNP was more strongly associated with CVD outcome than CRP, particularly among those with pre-
existing CVD. Inclusion of NT-proBNP in a Framingham-based model yielded significant improvement in
C-statistics in both men with and without CVD and resulted in a net reclassification improvement of 8.8% (p 
0.0009) and 8.2% (p  0.05), respectively, for major CVD events. Inclusion of CRP in the Framingham-based
model did not improve prediction in either group (net reclassification improvement 3.8% and 0.6%, respectively).
Conclusions NT-proBNP, but not CRP, improved prediction of major CVD events in older men with and without pre-existing
CVD. (J Am Coll Cardiol 2011;58:56–64) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.041There is intense interest in the use of “novel” blood marker
tests for assessing cardiovascular disease (CVD) risk both in
the general population and in high-risk groups such as those
with CVD (1). Two such markers include N-terminal
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2011, accepted February 10, 2011.pro-brain natriuretic peptide (NT-proBNP) and C-reactive
protein (CRP). NT-proBNP (2–16) and CRP (17,18) have
been shown to be strongly associated with risk of CVD in
both high-risk patients with established CVD and in the
general population. A recent systematic review based on
published findings showed that adding NT-proBNP or
BNP to predictive models containing conventional CVD
risk factors generally led to modest improvement in mea-
sures of risk discrimination (C-statistic) for subsequent
CVD (2), but the available data were sparse for generally
healthy populations (3,6,9). Furthermore, measures of risk
discrimination are only one way of assessing the perfor-
mance of a statistical prediction model (19), and more
clinical and descriptive measures, such as reclassification
metrics, can help to assess the clinical potential of adding a
new biomarker to a prediction model (19,20). Only a
limited number of studies, however, have evaluated the
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CVD risk in generally healthy people, and the clinical utility
of NT-proBNP in CVD risk stratification remains unclear
(3,5,10). Similar considerations apply to CRP, with con-
flicting data showing modest or no clinical utility (18). One
study attempted to directly compare CRP and NT-proBNP
for clinical utility but found that neither marker increased
discrimination as measured by only the C-statistic (9).
Finally, no studies have examined separately people with
and without baseline CVD within the same general popu-
lation, which may be important because of reverse causation
bias (particularly for NT-proBNP).
We therefore aimed to resolve outstanding uncertainties
in 2 ways. First we examined the independent relationship
between NT-proBNP and risk of CVD in the British
Regional Heart Study separately in men with and without
CVD with adjustment for a wide range of CV risk factors.
Then we directly compared NT-proBNP and CRP as CVD
risk markers by: 1) comparing marker associations with
CVD and coronary heart disease (CHD) (including fatal
events) outcomes separately in men with and without
baseline CVD; 2) comparing marker ability to improve the
C-statistic in a basic clinical CVD risk model in both men
with and without baseline CVD; and 3) comparing markers
in similar reclassification models.
Methods
The British Regional Heart Study is a prospective study of
CVD involving 7,735 men, screened between 1978 and 1980,
age 40 to 59 years drawn from 1 general practice in each of 24
British towns (21). The population studied was socioeconom-
ically representative of British men but consisted almost en-
tirely of white Europeans (99%). In 1998 to 2000, all
surviving men, now age 60 to 79 years, were invited for a 20th
year follow-up examination. All men completed a mailed
questionnaire providing information on their lifestyle and
medical history, had a physical examination, and provided a
fasting blood sample collected using the Sarstedt Monovette
system (Sarstedt, Numbrecht, Germany). The samples were
frozen and stored at 20°C on the day of collection and
ransferred in batches for storage at 70°C until analysis.
welve-lead electrocardiograms were recorded using a Sie-
ens Sicard 460 instrument (Siemens, Erlangen, Germany)
nd analyzed and coded in accordance with Minnesota Coding
efinitions at the University of Glasgow. The men were asked
hether a doctor had ever told them that they had angina or
yocardial infarction (MI) (heart attack, coronary thrombo-
is), heart failure, or stroke; they were also asked to bring their
edications to the examination session. A total of 4,252 men
77% of survivors) attended an examination, and blood serum
amples were available from 4,088 men. Because of sample
ttrition, NT-proBNP measurement on serum was conducted
n 3,761 men. Of these men, 112 with pre-existing self-
eported heart failure at baseline were excluded to reduce the ootential for nonatherothrombotic
everse causal associations with
VD risk, leaving 3,649 men for
he present analyses.
V risk factors. Anthropomet-
ic measurements including body
eight, height, and waist cir-
umference were performed. De-
ails of measurement and classi-
cation methods for smoking
tatus, physical activity, body
ass index (BMI), waist circum-
erence, social class, alcohol in-
ake, blood pressure, and blood
ipids in this cohort have been
escribed (22–24). Prevalent di-
betes included men with a diag-
osis of diabetes or men with
asting blood glucose 7 mmol/l.
RP was assayed by ultra-sensitive
ephelometry (Dade Behring,
ilton Keynes, United King-
om) (24). Estimated glomerular
ltration rate (eGFR), estimated from serum creatinine
sing the modification of diet in renal disease equation
eveloped by Levy et al. (25) was used as a measure of renal
unction. Anemia was defined as hemoglobin levels 13
/dl. Self-reported previous CVD events were used to
lassify those with pre-existing CVD at baseline.
T-proBNP. NT-proBNP levels were determined using
he Elecsys 2010 electrochemiluminescence method (Roche
iagnostics, Burgess Hill, United Kingdom). Samples were
nap-thawed at 37°C and assayed on the analyzer, which
as calibrated using the manufacturer’s reagents. Manufac-
urer’s controls were used to monitor assay drift, using both
high and low control, with limits of acceptability defined
y the manufacturer. Low control coefficient of variance was
.7%, and high control coefficient of variance was 4.9%.
ollow-up. All men have been followed from the initial
xamination (1978 to 1980) for CV morbidity, and follow-up
as been achieved for 99% of the cohort (26). In the present
nalyses, all-cause mortality and morbidity events are based on
ollow-up from rescreening in 1998 to 2000 at age 60 to 79
ears to July 2008, a mean follow-up period of 9 years (range
to 10 years). Information on death was collected through the
stablished “tagging” procedures provided by the National
ealth Service registers. Fatal stroke episodes were those
oded on the death certificate to International Classification of
iseases (ICD) 430 to 438. Nonfatal stroke events were those
hat produced a neurological deficit that was present for more
han 24 h. Fatal CHD was defined as death with CHD
ICD-9 410 to 414) as the underlying code. A nonfatal MI was
iagnosed according to World Health Organization criteria
27). CV deaths included all of those with ICD-9 401 to 459.
vidence regarding nonfatal MI and nonfatal stroke was
Abbreviations
and Acronyms
BMI  body mass index
CHD  coronary heart
disease
CRP  C-reactive protein
CVD  cardiovascular
disease
eGFR  estimated
glomerular filtration rate
FEV1  forced expiratory
volume in 1 s
HDL  high-density
lipoprotein
IDI  integrated
discrimination improvement
MI  myocardial infarction
NRI  net reclassification
improvement
NT-proBNP  N-terminal
pro brain natriuretic
peptidebtained from ongoing reports from general practitioners,
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NT-proBNP, CRP, and Cardiovascular Risk June 28, 2011:56–64biennial reviews of the patients’ practice records (including
hospital and clinic correspondence) through the end of the
study period, and repeated personal questionnaires to surviving
patients after the initial examination. Outcomes assessed in the
current analyses were major CHD (defined as fatal or nonfatal
MI), major stroke events (fatal or nonfatal), CVD death, and
all major CVD events (major CHD events, stroke events, or
CVD death).
Statistical methods. The distribution of NT-proBNP and
CRP was skewed, and log transformation was used. The
Cox proportional hazards model was used to assess the
multivariate-adjusted hazard ratio (relative risk [RR]) in a
comparison of quartiles of NT-proBNP and for a 1-SD
increase in NT-proBNP and CRP levels. In multivariate
analyses, smoking (never, long-term ex-smokers [15
ears], recent ex-smokers [15 years], and current smok-
Baseline Characteristics According to Quartiles of NT-proBNP ConcTable 1 Baseline Characteristics According to Quartiles of NT-
Without CVD, pg/ml 40 41
Age, yrs 65.5 67
Smokers, % 10.6 11
Inactive, % 28.9 27
High alcohol consumption, % 3.5 3
Diabetes, % 10.3 9
Atrial fibrillation, % 0.3 0
Anemia, % 2.4 3
Body mass index, kg/m2 26.9 26
Waist circumference, cm 96.9 96
Systolic blood pressure, mm Hg 142.8 147
HDL cholesterol, mmol/l 1.32 1
Total cholesterol, mmol/l 6.27 6
Triglyceride, mmol/l 1.77 1
Glucose, mmol/l 5.81 5
FEV1, l 2.81 2
CRP, mg/l* 1.32 1
eGFR, ml/min 75.1 74
With CVD, pg/ml 85 86–
Age, yrs 67.6 68
Smokers, % 10.9 9
Inactive, % 32.8 48
High alcohol consumption, % 2.1 4
Diabetes, % 13.0 13
Atrial fibrillation, % 1.6 0
Anemia, % 8.3 7
Body mass index, kg/m2 28.0 27
Waist circumference, cm 99.9 97
Systolic blood pressure, mm Hg 142.9 144
HDL cholesterol, mmol/l 1.26 1
Total cholesterol, mmol/l 5.83 5
Triglyceride, mmol/l 1.77 1
Glucose, mmol/l 5.99 5
FEV1, l 2.64 2
CRP, mg/l* 1.99 1
eGFR, ml/min 72.9 71
*Geometric mean.
CRP  C-reactive protein; CVD  cardiovascular disease; eGFR  estimated glomerular filtration rate;
ro-brain natriuretic peptide.rs), social class (manual vs. nonmanual labor), physical
ctivity (4 groups), alcohol intake (5 groups), diabetes
yes/no), BMI (25, 25 to 27.5, 27.5 to 29.9, and 30
g/m2), anemia (yes/no), and eGFR (60, 60 to 69, and
70 ml/min/1.73 m2) were fitted as categorical variables;
NT-proBNP (log), forced expiratory volume in 1 s (FEV1),
igh-density lipoprotein (HDL) cholesterol, and CRP (log)
ere fitted as continuous variables. To assess the clinical
tility of NT-proBNP (or CRP) in CVD risk prediction,
e performed a series of analyses. Receiver-operating char-
cteristic (ROC) curves and areas under the curve
C-statistics) were used to assess the ability of NT-proBNP
and CRP) to predict CVD beyond established risk factors
ncluded in the Framingham score (28). We calculated risk
unction estimates based on the regression coefficients of the
ramingham-based Cox models with and without
tion in Men With and Without Pre-Existing CVDP Concentration in Men With and Without Pre-Existing CVD
T-proBNP Quartiles p Trend
78–150 151
69.0 71.1 0.0001
13.1 14.8 0.07
29.9 38.9 0.0001
3.9 5.4 0.22
9.0 13.9 0.008
0.4 9.0 0.0001
6.8 14.4 0.0001
26.7 26.6 0.02
96.8 96.5 0.23
151.6 158.1 0.0001
1.33 1.35 0.05
6.03 5.89 0.0001
1.55 1.52 0.0001
5.87 5.87 0.13
2.63 2.43 0.0001
1.68 2.27 0.0001
73.0 69.8 0.0001
178–383 384
69.9 73.2 0.0001
14.7 10.6 0.43
49.2 42.2 0.006
2.1 1.1 0.22
13.7 16.0 0.85
2.1 19.2 0.0001
11.6 9.6 0.48
27.3 26.9 0.02
98.2 97.9 0.24
146.6 148.6 0.002
1.25 1.26 0.81
5.62 5.70 0.03
1.68 1.58 0.004
6.05 5.87 0.48
2.43 2.30 0.0001
2.01 2.51 0.003
69.9 64.4 0.0001entraproBN
N
–77
.3
.3
.2
.5
.3
.1
.3
.7
.7
.7
.34
.15
.63
.81
.70
.40
.0
177
.8
.7
.1
.3
.4
.1
.1
.0
.3
.28
.79
.79
.92
.54
.68
.5FEV1  forced expiratory volume in 1 s; HDL  high-density lipoprotein; NT-proBNP  N-terminal
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June 28, 2011:56–64 NT-proBNP, CRP, and Cardiovascular RiskNT-proBNP (CRP) in the model. We constructed ROC
curves and computed the areas under the curve (C-statistics)
for predicting CVD events for the risk function estimates.
Tests for differences between the C-statistics for
established-based risk function models with and without
NT-proBNP (CRP) were performed using an SAS macro
(%ROC) with SAS software (version 9.1, SAS Institute,
Inc., Cary, North Carolina). Then we addressed the issue of
how NT-proBNP (or CRP) evaluation may alter the risk
stratification of men. All men were categorized according to
3 risk groups based on their 10-year predicted probabilities
(10%, 10% to 19%, and 20%) obtained from risk
function models for CVD events with and without NT-
proBNP (or CRP). We evaluated the ability of NT-
proBNP (and CRP) to reclassify risk using methods sug-
gested by Pencina et al. (29) by calculating the net
reclassification improvement (NRI) and the integrated dis-
crimination improvement (IDI).
Results
Baseline characteristics by NT-proBNP levels. Table 1
shows the baseline characteristics according to quartiles of
NT-proBNP concentration in men with and without CVD.
Incidence Rates per 1,000 Person-Years (Number of Cases) and AdMajor CVD Ev nts by Quartiles of NT-p oB P in Men Without DiagnTable 2 Incidence R tes per 1,000 Person-Years (Number of CMajor CVD Events by Quartiles of NT-proBNP in Men W
NT-p
<40 41–77
Total no. of patients 710 735
Major CVD events
Rate/1,000 person-yrs 8.9 (55) 11.8 (73)
Age-adjusted 1.00 1.17 (0.82–1.67)
Model 1 1.00 1.14 (0.80–1.63)
Model 2 1.00 1.12 (0.78–1.59)
CVD mortality
Rate/1,000 person-yrs 3.1 (20) 4.5 (29)
Age-adjusted 1.00 1.20 (0.68–2.12)
Model 1 1.00 1.15 (0.64–2.07)
Model 2 1.00 1.14 (0.63–2.04)
Major CHD events
Rate/1,000 person-yrs 4.6 (29) 5.7 (36)
Age-adjusted 1.00 1.12 (0.69–1.83)
Model 1 1.00 1.07 (0.65–1.75)
Model 2 1.00 1.04 (0.64–1.71)
Fatal CHD
Rate/1,000 person-yrs 1.9 (12) 2.9 (18)
Age-adjusted 1.00 1.25 (0.60–2.60)
Model 1 1.00 1.13 (0.54–2.36)
Model 2 1.00 1.14 (0.54–2.38)
Major stroke
Rate/1,000 person-yrs 3.3 (21) 5.1 (32)
Age-adjusted 1.00 1.33 (0.77–2.32)
Model 1 1.00 1.26 (0.72–2.20)
Model 2 1.00 1.24 (0.71–2.16)
Model 1 was adjusted for age, smoking status, physical activity, alcohol intake, body mass index,
he same variables plus CRP, anemia, atrial fibrillation, and renal dysfunction (eGFR).
CHD  coronary heart disease; HR  hazard ratio; other abbreviations as in Table 1.Raised NT-proBNP levels were strongly associated with
many adverse CV risk factors including age, physical inac-
tivity, atrial fibrillation, systolic blood pressure, lung func-
tion (FEV1), CRP level, and eGFR in both groups of men.
However, NT-proBNP was inversely associated with BMI,
cholesterol level, and triglyceride level.
Follow-up CVD events in men with and without baseline
CVD. During the mean follow-up time of 9 years, there
were 194 major CHD events (119 fatal; 61.3% case fatality),
158 major stroke events, 223 CVD deaths, and 402 major
CVD events (stroke, CHD, and CVD deaths) in the 2,893
men with no pre-existing CVD. In men with pre-existing
CVD, there were 110 major CHD events (85 fatal; 77.3%
case fatality), 74 major stroke events, 150 CVD deaths, and
206 major CVD events.
NT-proBNP associations with CVD risk. Men with
pre-existing CVD (MI, angina, or stroke; n  756) had
igher levels of NT-proBNP than those without (n 
,893); geometric means were 181.3 (interquartile range: 85
o 379) pg/ml and 81.5 (interquartile range: 41 to 151)
g/ml, respectively (p  0.0001). Table 2 shows the
elationship between NT-proBNP and major CVD events,
ajor CHD events (nonfatal MI or CHD death), fatal
d HRs (95% Confidence Intervals) forCVD and With ut Diagnosis of Heart Failure) and Adjusted HRs (95% Confidence Intervals) for
t Diagnosed CVD and Without Diagnosis of Heart Failure
Quartiles, pg/ml
p Trend78–150 >151
723 725
16.8 (99) 32.8 (175)
1.44 (1.03–2.03) 2.49 (1.80–3.44) 0.0001
1.30 (0.92–1.84) 2.00 (1.43–2.80) 0.0001
1.24 (0.88–1.76) 1.77 (1.25–2.50) 0.0001
7.3 (45) 23.1 (129)
1.55 (0.91–2.66) 4.10 (2.50–6.74) 0.0001
1.37 (0.79–2.39) 3.17 (1.89–5.35) 0.0001
1.29 (0.74–2.25) 2.64 (1.56–4.47) 0.0001
7.3 (44) 15.5 (85)
1.28 (0.79–2.08) 2.47 (1.58–3.88) 0.0001
1.12 (0.68–1.83) 1.88 (1.18–3.00) 0.0001
1.06 (0.65–1.73) 1.61 (1.00–2.60) 0.0001
3.7 (22) 12.2 (67)
1.31 (0.64–2.68) 3.72 (1.94–7.13) 0.0001
1.00 (0.48–2.08) 2.45 (1.26–4.77) 0.0001
0.95 (0.46–1.97) 1.98 (1.01–3.93) 0.0001
7.2 (43) 11.5 (62)
1.60 (0.94–6.74) 2.23 (1.32–3.78) 0.0001
1.42 (0.83–2.46) 1.77 (1.03–3.06) 0.004
1.38 (0.80–2.39) 1.61 (0.92–2.82) 0.01
blood pressure, HDL cholesterol, total cholesterol, FEV1, and diabetes. Model 2 was adjusted forjusteosedases
ithou
roBNP
systolic
a60 Wannamethee et al. JACC Vol. 58, No. 1, 2011
NT-proBNP, CRP, and Cardiovascular Risk June 28, 2011:56–64CHD events, and all CV mortality in men without CVD.
High NT-proBNP level (highest quartile) was associated
with significantly increased risk of all major CVD events,
CVD mortality, major CHD events, fatal CHD events, and
major stroke events even after adjustment for CV risk
factors (age, smoking status, physical activity, alcohol in-
take, BMI, systolic blood pressure, HDL cholesterol, total
cholesterol, FEV1, and diabetes). Further adjustment for
CRP, renal dysfunction, atrial fibrillation, and anemia made
minor differences to the strength of the association
(Table 2). In a sensitivity analysis, no significant association
was seen with nonfatal MI (n  75 events) in a model
adjusted for CV risk factors (adjusted RR: 1.00, 1.08 [95%
confidence interval (CI): 0.55 to 2.60], 1.40 [95% CI: 0.73
to 2.68], and 1.27 [95% CI: 0.63 to 2.58] for the 4 quartiles,
respectively). No association was seen between elevated
NT-proBNP level and non-CVD mortality (adjusted RR:
1.00, 1.00 [95% CI: 0.73 to 1.37], 1.04 [95% CI: 0.76 to
1.42], and 1.22 [95% CI: 0.89 to 1.66]). Like NT-proBNP,
CRP level was significantly associated with all CV end-
points (except nonfatal MI) after adjustment for risk factors
including NT-proBNP (data not shown). However, in
contrast to NT-proBNP, CRP related significantly to non-
CVD mortality (adjusted RR: 1.00, 1.19 [95% CI: 0.87 to
Incidence Rates per 1,000 Person-Years (Number of Cases) and Adfor Major CVD Events by Quartiles of NT-proBNP in Men With DiagnTable 3 Incid ce Rates per 1,000 Person-Years (Number of Cfor Major CVD Events by Quartiles of NT-proBNP in Me
NT
<85 86–177
Total no. of patients 192 186
Major CVD events
Rate/1,000 person-yrs 15.8 (25) 31.7 (46)
Age-adjusted 1.00 1.89 (1.16–3.07)
Model 1 1.00 1.77 (1.07–2.92)
Model 2 1.00 1.75 (1.06–2.90)
CVD mortality
Rate/1,000 person-yrs 6.1 (10) 18.5 (28)
Age-adjusted 1.00 2.89 (1.40–5.95)
Model 1 1.00 2.71 (1.30–5.64)
Model 2 1.00 2.76 (1.32–5.75)
Major CHD events
Rate/1,000 person-yrs 6.2 (10) 16.7 (25)
Age-adjusted 1.00 2.59 (1.24–5.60)
Model 1 1.00 2.39 (1.13–5.09)
Model 2 1.00 2.42 (1.13–5.15)
Fatal CHD
Rate/1,000 person-yrs 1.9 (3) 13.4 (20)
Age-adjusted 1.00 6.81 (2.02–22.90)
Model 1 1.00 6.07 (1.79–20.65)
Model 2 1.00 5.87 (1.72–20.05)
Major stroke
Rate/1,000 person-yrs 8.7 (14) 13.6 (20)
Age-adjusted 1.00 1.45 (0.73–2.87)
Model 1 1.00 1.47 (0.72–2.97)
Model 2 1.00 1.43 (0.70–2.94)
Model 1 was adjusted for age, smoking status, physical activity, alcohol intake, body mass index, sy
nd stroke. Model 2 was adjusted for the same variables plus CRP, anemia, atrial fibrillation, and renal d
Abbreviations as in Tables 1 and 2.1.63], 1.34 [95% CI: 0.98 to 1.83], and 1.49 [95% CI: 1.10
to 2.03] for the 4 quartiles of CRP, respectively).
In men with CVD but no diagnosed heart failure (Table 3),
risk of major CHD and CVD events, fatal CHD events,
and CVD mortality increased significantly with increasing
levels of NT-proBNP, even after full adjustment. No
association was seen with non-CVD mortality (p  0.51).
CRP showed no significant association with any CVD
outcome or mortality after adjustment for CV risk factors in
these men.
For comparison with CRP and assessment of the risk
prediction of CVD beyond Framingham risk score, Table 4
shows the standardized hazard ratio for a 1-SD change in
log CRP and NT-proBNP after adjustment for established
risk factors included in the Framingham risk score in men
with and without pre-existing CVD and the improvement
in C-statistics in models with and without NT-proBNP (or
CRP). NT-proBNP was a stronger predictor of major
CHD and CVD mortality than CRP, particularly in those
with pre-existing CVD. In men without CVD, NT-
proBNP added significantly to CVD events and CVD
mortality prediction but not to major CHD events after
inclusion of risk factors. In men with CVD, NT-proBNP
added significantly to prediction of both major CHD and
d HRs (95% Confidence Intervals)CVD and With ut Diagnosis of Heart Failure) and Adjusted HRs (95% Confidence Intervals)
h Diagnosed CVD and Without Diagnosis of Heart Failure
P Quartiles, pg/ml
p Trend178–383 >384
190 188
38.5 (52) 70.9 (83)
2.13 (1.32–3.45) 3.25 (2.04–5.20) 0.0001
1.76 (1.07–2.89) 2.85 (1.76–4.62) 0.0001
1.75 (1.06–2.88) 2.85 (1.73–4.69) 0.0001
26.4 (38) 60.4 (74)
3.78 (1.88–7.62) 7.24 (3.68–14.26) 0.0001
2.83 (1.37–5.83) 6.45 (3.24–12.84) 0.0001
2.84 (1.38–5.86) 6.79 (3.37–13.65) 0.0001
19.0 (27) 40.1 (48)
2.79 (1.34–5.78) 5.06 (2.49–10.23) 0.0001
2.23 (1.05–4.75) 4.57 (2.23–9.38) 0.0001
2.10 (0.98–4.50) 4.51 (2.14–9.52) 0.0001
14.8 (21) 34.3 (41)
6.96 (2.07–23.39) 13.23 (4.03–43.51) 0.0001
4.81 (1.40–16.53) 11.52 (3.47–38.29) 0.0001
4.46 (1.29–15.41) 11.07 (3.28–37.28) 0.0001
14.6 (20) 16.7 (20)
1.40 (0.70–2.78) 1.31 (0.64–2.68) 0.06
1.19 (0.57–2.48) 1.19 (0.57–2.48) 0.18
1.19 (0.57–2.48) 1.06 (0.48–2.38) 0.24
lood pressure, HDL cholesterol, total cholesterol, FEV1, diabetes, pre-existing myocardial infarction,justeosedases
n Wit
-proBN
stolic b
ysfunction (eGFR).
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June 28, 2011:56–64 NT-proBNP, CRP, and Cardiovascular RiskCVD events and CVD mortality. By contrast, CRP did not
add significantly to prediction after inclusion of traditional
risk factors in men with or without CVD. When we tested
CRP and NT-proBNP jointly in predicting all CVD events,
we noted that adding CRP to a model that included
NT-proBNP provided no further improvement in predic-
tion (p  0.12). By contrast, adding NT-proBNP to a
odel that included CRP improved prediction significantly
p  0.03).
Table 5 shows the cross-tabulation between predicted
isk obtained using the risk function based on established
isk markers used in Framingham with and without NT-
roBNP (or CRP) in cases and noncases in men with and
ithout pre-existing CVD. In men with no pre-existing
VD, the overall NRI was estimated at 8.8% for NT-
roBNP (p  0.01) (NRI for events was 7.3%, and NRI for
Adjusted Standardized HRs for 1-SD Increases iand log CRP and C-StatisticsTable 4 A justed Standardized HRs for 1-SDand log CRP and C-Statistics
Standardized HR for
CRP/proBNP (95% CI)
Men with no CVD
All major CVD events
Model A
Model A  CRP 1.22 (1.10–1.34)
Model A  NT-proBNP 1.49 (1.33–1.65)
CVD mortality
Model A
Model A  CRP 1.28 (1.14–1.44)
Model A  NT-proBNP 1.86 (1.62–2.11)
Major CHD events
Model A
Model A  CRP 1.19 (1.03–1.36)
Model A  NT-proBNP 1.48 (1.28–1.73)
Fatal CHD
Model A
Model A  CRP 1.27 (1.09–1.49)
Model A  NT-proBNP 1.72 (1.44–2.07)
Men with CVD
All major CVD events
Model B
Model B  CRP 1.00 (0.86–1.38)
Model B  NT-proBNP 1.52 (1.33–1.75)
CVD mortality
Model B
Model B  CRP 1.06 (0.91–1.24)
Model B  NT-proBNP 1.88 (1.61–2.20)
Major CHD events
Model B
Model B  CRP 0.98 (0.82–1.17)
Model B  NT-proBNP 1.61 (1.35–1.93)
Fatal CHD
Model B
Model B  CRP 0.97 (0.80–1.18)
Model B  NT-proBNP 1.77 (1.43–2.19)
Model A includes age, smoking status, systolic blood pressure, HDL cho
plus pre-existing myocardial infarction and stroke.
Abbreviations as in Tables 1 and 2.on-CV events was 1.5%). The IDI was 2.33 and wassignificant (p  0.0001). For CRP, the overall NRI was
mall (3.8%; p  0.07) and the IDI was nonsignificant
0.32; p  0.14). In men with pre-existing CVD, the net
gain reclassification for NT-proBNP was estimated at 8.2%
(p  0.049) for all CVD events, and the IDI was also
significant (4.38; p  0.0001); for CRP, the NRI for all
CVD events was 0.6% (p  0.71) and the IDI was
significant but negative (0.88; p  0.001).
Discussion
We have conducted an in-depth analysis of the predictive
ability of NT-proBNP in a large population-based study of
men with and without CVD; given the large number of
events, results add usefully to the findings of a recent
meta-analysis on this topic (2). Our results suggest that
NT-proBNPeases in log NT-proBNP
p Trend C-Statistics
Improvement in
C-Statistics
0.686
0.0001 0.695 p 0.06
0.0001 0.704 p 0.01
0.753
0.0001 0.765 p 0.05
0.0001 0.784 p 0.002
0.686
0.01 0.690 p 0.49
0.0001 0.694 p 0.42
0.751
0.0004 0.771 p 0.13
0.0001 0.772 p 0.16
0.689
0.96 0.690 p 0.70
0.0001 0.728 p 0.004
0.712
0.47 0.713 p 0.50
0.0001 0.778 p 0.0002
0.669
0.85 0.671 p 0.58
0.0001 0.714 p 0.01
0.686
0.75 0.687 p 0.81
0.0001 0.738 p 0.007
l, total cholesterol, and diabetes. Model B includes the same variablesn logIncr
lesteroNT-proBNP is more strongly associated than CRP with
ions as
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a more specific signal for CVD risk (seen for both major
CHD and stroke events), and provides greater incremental
clinical utility than CRP for CVD risk assessment in older
men. Among men with no history of CVD, the C-statistic
for risk of all CVD events improved significantly when
NT-proBNP was added to a (Framingham-based) model;
NRI also improved, whereas CRP did not significantly
improve either. These results suggest a genuine potential for
NT-proBNP to offer potential prognostic value beyond
established clinically applicable markers, and this question
therefore deserves further detailed study, including cost
effectiveness of such an approach, in other cohorts.
As a CVD risk marker, NT-proBNP is pragmatically
attractive for many of the same reasons as is CRP in that it
can be routinely measured (currently to rule out heart failure
diagnosis on admission) and there are robust and reproduc-
ible assays available commercially. In addition, from a
biological point of view, release of BNP in patients with
vascular disease is considered to be primarily a result of
myocardial stretch and physiological stress to produce a
natriuretic and diuretic effect (via the physiologically active
BNP fragment, along with the inactive NT-proBNP frag-
ment). To what extent subclinical cardiac stress also explains
Reclassification Among Men Who Develop Major CVD Events and Ton Follow-Up in Men With a d Without Pre-Existing CVDTable 5 Reclassificatio Am ng Men Who Develop Major CVDon Follow-Up in Men With and Without Pre-Existing CV
Basic Model 1  NT-proBNP
Basic model 1 10% 10%–20%
Noncases
10% 935 (95.2) 158 (14.4)
10%–20% 189 (21.9) 564 (65.2) 1
20% 0 122 (24.7) 3
Cases
10% 60 (69.8) 25 (29.1)
10%–20% 13 (9.7) 85 (63.4)
20% 0 20 (11.4) 1
NRI  8.8%; p  0.0009
IDI  2.33; p  0.0001
Basic Model 2  NT-proBNP
Basic model 2 20% 20–30%
Noncases
20% 170 (79.4) 36 (16.8)
20%–30% 36 (26.7) 68 (50.4)
30% 15 (7.8) 39 (20.2) 1
Cases
20% 19 (59.4) 9 (28.1)
20%–30% 2 (4.6) 25 (56.8)
30% 0 17 (13.3) 1
NRI  8.2%; p  0.049
IDI  4.38; p  0.0001
Basic model 1 includes age, smoking status, systolic blood pressure, HDL cholesterol, total choles
stroke.
IDI  integrated discrimination index; NRI  net reclassification improvement; other abbreviatmore subtle elevations in NT-proBNP level needs to beproperly examined, however, because other pathways related
to the more complex physiological functions/interactions of
the natriuretic peptides may also play a role. Nevertheless, it
is of interest that increased NT-proBNP level is associated
with increased risk of CVD and CHD events after adjust-
ment for classical risk factors in older men (both with and
without baseline CVD) but not with non-CVD mortality.
By contrast, CRP is associated with both CVD and non-
CVD mortality and predicts noncardiac endpoints, includ-
ing several cancers and respiratory diseases (17).
That NT-proBNP is more predictive of CVD risk than
CRP, particularly among men with prevalent baseline CVD
(in whom CRP showed no predictive value), has also been
noted in other studies (7,9,10,14,15); NT-proBNP levels
will generally be elevated proportionally to the severity of
existing disease. However, the practical relevance of this
observation among those who have had an event previously
is uncertain. Clearly, most individuals who have previously
experienced a CVD event will be on a range of medications
(including statins, antihypertensives, beta blockers, and
aspirin). However, it is possible that those who are at
greatest risk may benefit from higher doses to meet more
stringent blood pressure and lipid targets or be most suitable
to test novel CVD protective modalities in future studies.
Who Do Not Experience CVD Eventsts and Those Who Do Not Experience CVD Events
Without Pre-Existing CVD
Basic Model 1  CRP
% 10% 10%–20% 20%
.5) 1,003 (91.7) 91 (8.3) 0
3.0) 117 (13.4) 666 (76.3) 90 (10.3)
5.4) 2 (0.4) 81 (16.5) 408 (83.1)
.2) 71 (79.8) 18 (20.2) 0
6.9) 5 (13.8) 99 (75.0) 28 (2.9)
8.6) 0 19 (10.9) 156 (89.1)
NRI  3.8%; p  0.07
IDI  0.32; p  0.14
en With Pre-Existing CVD
Basic Model 2  CRP
% 20% 20–30% 30%
.7) 206 (96.3) 8 (3.7) 0
3.0) 5 (3.7) 129 (94.9) 2 (1.5)
2.0) 4 (2.1) 11 (5.7) 177 (97.2)
2.5) 31 (96.9) 1 (3.1) 0
8.6) 2 (4.6) 42 (95.6) 0
6.7) 1 (0.8) 3 (2.3) 124 (96.9)
NRI  0.6%; p  0.71
IDI  0.88; p  0.001
nd diabetes. Basic model 2 includes the same factors plus presence of myocardial infarction and
in Table 1.hoseEven
D
Men
20
5 (0
12 (1
73 (7
1 (1
36 (2
56 (8
M
30
8 (3
31 (2
39 (7
4 (1
17 (3
11 (8
terol, aBecause the relative severity of underlying CVD (including
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June 28, 2011:56–64 NT-proBNP, CRP, and Cardiovascular Risksilent infarcts) in an apparently healthy patient may not always
be obvious to an examining clinician, the information provided
by NT-proBNP may also be useful in primary prevention risk
prediction. It is also possible that NT-proBNP levels may in
part reflect increased vascular risk associated with other comor-
bidities such as rheumatoid arthritis. These possibilities require
further study. However, adjustment for medication for joint
disorders made little difference to the findings.
NT-proBNP showed trends to be more strongly associ-
ated with fatal CVD and CHD events compared with
nonfatal CHD events in men with and without baseline
CVD, which is similar to trends previously noted for
inflammatory markers (30). This observation suggests that
studies with only fatal endpoints are more likely to report
stronger associations of BNP or NT-proBNP with incident
events than studies with combined fatal and nonfatal events.
This observation may also explain inconsistencies among
studies and why significant improvement in risk stratifica-
tion for primary CVD events tend to be observed in studies
with older patients in whom case fatality is high (10) or in
studies reporting on only fatal CVD endpoints (6).
Study strengths and limitations. Strengths and limita-
tions of the study require consideration. This study is based
on a cohort of older (age 60 to 79 years) men. Although this
is a group of considerable clinical interest because they
constitute a high-risk group in whom traditional risk factors
become less predictive (31), our results need further confir-
mation in similar study populations, middle-aged popula-
tions, and women. The study population is socially repre-
sentative of the United Kingdom, and follow-up rates in the
British Regional Heart Study were exceptionally high.
Ascertainment of CHD death and MI was based on
standard methods, and both CHD mortality and MI
incidence rates corresponded closely with national data.
Conclusions
The results of this study suggest that NT-proBNP has a
greater potential to improve prediction of major CVD
events than does CRP in older men with and without
pre-existing CVD. These results may have clinical rele-
vance, and other groups should now extend our observations
in other prospective cohorts to establish whether NT-
proBNP is indeed able to enhance risk prediction across a
range of populations in a clinically meaningful, and cost-
effective, manner. If so, future collaborative ventures may
also be able to ascertain how to optimally introduce NT-
proBNP into clinical CVD risk prediction.
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